News

Find out about our current activities

Click on the news below to find out more about our current activities and media coverage.

Nature Scientific Reports Publication Touts Versatility, Promise of 3D Human Liver Microtissues for Drug Development

Nature Scientific Reports Article Touts Versatility, Promise of 3D Human Liver Microtissues for Drug Development

Schlieren, Switzerland, June 16, 2016 – Liver spheroids display longer culture lifetime, liver-like functionality, and increased sensitivity for detection of hepatotoxic drugs.  PDF Version

Research published by the Karolinska Institute and collaborators as part of the European Community Innovative Medicine Initiative project (MIP-DILI) offers further, independent verification of the utility and promise of 3D liver microtissues for studying liver function, liver diseases and long-term drug-induced liver injury (DILI). The research was published last month in Nature Scientific Reports, an open-access journal.

The paper demonstrates the extended in vitro lifetime and organotypic characteristics of primary human hepatocytes (PHH) when cultured in a scaffold-free 3D configuration, displaying viability and liver-like functionality for up to five weeks in culture. Proteomic analysis revealed that inter-individual variability was retained between spheroids generated from different individual hepatocyte donors. The study also used the prolonged in vitro lifespan of 3D cultured hepatocytes to perform chronic exposure testing of known DILI-inducing drugs, and found they could predict toxicity at clinically-relevant doses. In addition, the spheroid model system proofed to be suitable for studying liver diseases such as cholestasis and steatosis.

Commenting on the publication, Dr. Jens M. Kelm, Chief Scientific Officer and co-founder of InSphero AG says the paper, “Reinforces to the scientific community the benefits of 3D liver microtissues for the purpose of safety assessment during drug development. 3D liver models show enhanced culture lifetime in comparison to standard 2D cultured hepatocytes. This allows for long-term, repeat dose exposure studies, and enhances the sensitivity and predictive power of the model.”

InSphero uses its patent-pending 3D Select™ Process to enable industrial-scale production of 3D liver microtissues for in vitro liver research and DILI testing conducted by the world’s largest pharmaceutical and chemical companies. Dr. Kelm notes that InSphero has performed similar proteomic and genomic characterization of its 3D InSight™ Human Liver Microtissues grown over 28 days in culture, results presented at the EuroTox Annual Meeting in 2015. InSphero’s 3D Select™ Process yields liver microtissues with consistent morphology and viability by ensuring only the healthiest cells incorporate into tissues, a critical difference from conventional methods. “Cryopreserved hepatocytes contain large numbers of necrotic and functionally compromised cells. This percentage varies greatly between donor lots and vendors, making it challenging to make uniform microtissues in the numbers needed for industrial-scale testing. Through our 3D Select™ Process, we remove these compromised cells prior to the aggregation step, making microtissue formation more reliable, while improving morphology and viability. This translates to a more robust, mechanistically accurate in vitro model that enables testing standardization across multiple sites, and across the industry as a whole.”

To find out more about 3D InSight™ Human Liver Microtissues, the 3D Select™ Process, or to learn more about InSphero visit www.insphero.com.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

EY World Entrepreneur Of The Year™ 2016: Dr. Jan Lichtenberg to represent Swiss entrepreneurs

ey logo detail

InSphero CEO, Dr. Jan Lichtenberg has been nominated to represent Swiss entrepreneurs at EY World Entrepreneur Of The Year™ 2016 in Monte Carlo. The winner will be announced on 11 June 2016.

pic Jan for PRZURICH, 6 JUNE 2016 – EY World Entrepreneur Of The Year™ is a global platform that highlights the great importance of entrepreneurs in every economy. Each year, a distinguished international jury selects the best of the best from a field of more than 60 nominated winners of national Entrepreneur of the Year competitions. Based on the criteria of entrepreneurial spirit, financial performance, strategy, impact on the global and local environment, innovation and personal integrity and social commitment, the jury evaluates who has ultimately set global standards from a personal and entrepreneurial standpoint.

Read full press release in English

Read full press release in German

Read full press release in French

More about the EY Entrepreneur Of The Year™ competition:
The Entrepreneur Of The Year competition has been held in Switzerland since 1998, with around 45 entrepreneurs nominated each year. In 2008, a Swiss entrepreneur was named World Entrepreneur Of The Year™ when Dr. Jean-Paul Clozel, founder and CEO of Actelion Pharmaceuticals Ltd. won the award.

 

InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury

InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury

Schlieren, Switzerland, March 16, 2016 – 3D human liver microtissues comprised of pooled hepatocytes from multiple donors offers more genetically diverse model for DILI detection and prediction.  PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, today announced the launch of 3D InSight™ Multi-donor Human Liver Microtissues, further expanding the company’s catalog of organotypic 3D models produced using their patented hanging-drop production technology. The newest liver model is being introduced at the Society of Toxicology’s 55th Annual Meeting and ToxExpo being held this week in New Orleans, Louisiana. Failure of drugs during late phases of the drug discovery process costs the pharmaceutical industry billions of dollars each year, and drug-induced liver injury (DILI) is the primary reason for post-market drug withdrawal. InSphero 3D InSight™ Human Liver Microtissues provide a more sensitive preclinical in vitro model for DILI detection and prediction, with the specificity to accurately distinguish between known hepatotoxicants and structurally-related non-toxic analogs. The new multi-donor microtissues offer the same structural and functional robustness of single-donor microtissues, but provide a more diverse genetic background to help mitigate bias in models resulting from naturally occurring variations in drug-metabolizing Cytochrome P450 enzymes.

Dr. Jens Kelm, InSphero Chief Scientific Officer and co-founder says, “By pooling hepatocytes from 5 male and 5 female donors, multi-donor microtissues more closely approximate the average human response, and extend donor lot availability to ensure a long-term supply of cells for microtissue production. This makes them an ideal tool for in vitro DILI detection and prediction, compound toxicity screening, mechanistic toxicology, and DMPK studies.”

Multi-donor microtissues are available as hepatocyte-only monocultures, or as co-cultures with Kupffer cells, enabling detection of immune-mediated toxicity.

To find out more about 3D InSight™ Multi-donor Human Liver Microtissues, or to learn more about InSphero visit www.insphero.com.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

Images

multi donor modified2 no backgroundmulti donor icon balanced5

InSphero Contributes 3D Microtissue-based Assay Chapter to NCATS/NIH Assay Guidance Manual

InSphero Contributes 3D Microtissue-based Assay Chapter to NCATS/NIH Assay Guidance Manual

Schlieren, Switzerland, February 10, 2016 – Latest update of industry manual for development of high-throughput screening calls on scientists from leading 3D cell culture provider for standardized viability, toxicity protocols.  PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has contributed a chapter in the NIH National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual, which describes best practices for adapting and standardizing high-throughput assays for use with 3D microtissues. The chapter, “In vitro 3D Spheroids and Microtissues: ATP-based Cell Viability and Toxicity Assays,” was co-authored by Dr. Monika Kijanska and Dr. Jens M. Kelm of InSphero, and appears in a 2016 update to the eBook published last week.

Dr. Terry Riss, Global Strategic Marketing Manager, Cell Health at Promega Corporation, and a contributing editor for the Assay Guidance Manual states, “The new chapter by Drs. Kijanska and Kelm provides expert guidance for scientists moving into the realm of using more physiologically relevant 3D cell culture model systems, and fills a long overdue gap in the content of the Assay Guidance Manual.” Dr. Kelm, Chief Scientific Officer and co-founder of InSphero said, “It was an honor to lend our expertise to such a well-recognized and widely accepted reference guide for cell-based assay and screening communities. It’s a great example of open innovation.” The chapter addresses considerations for choosing an appropriate 3D model, provides guidance on selection of reagents and protocol adaptations proven to work in a 3D setting, and gives specific examples of cell viability and toxicity assay results obtained with InSphero 3D InSight™ Human Liver Microtissues and Tumor Microtissues.

Early iterations of the manual were created by staff researchers at Eli Lilly and Company, but content for the Assay Guidance Manual is currently edited by 19 researchers representing 11 institutions, including NCATS and Lilly. The manual provides guidelines for scientists in academic, non-profit, government and industrial research interested in developing assays useful in screening molecules that modulate biological targets, pathways, or cellular phenotypes. Such molecules may serve as candidates for development of novel drugs for diseases such as cancer, diabetes, neurodegenerative disease, and rare genetic disorders.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

InSphero Inc. Streamlines 3D Microtissue Business Operations in US

InSphero Inc. Streamlines 3D Microtissue Business Operations in US

Schlieren, Switzerland, February 01, 2016 – US subsidiary of Swiss-based InSphero AG initiates direct product shipments, progresses towards full-scale US bioproduction capabilities.. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has begun accepting orders and processing all financial transactions with customers in North America through its US subsidiary InSphero Inc. The February 1 transition immediately streamlines access to InSphero products and services for US-based customers, and positions the company to initiate operations in its recently completed US bioproduction laboratory in Brunswick, Maine.

Stewart Hunt, General Manager of InSphero Inc., states the transition, “Will dramatically simplify order fulfillment for customers in our largest market by allowing them to order directly from a US source. This eliminates customs processing, additional handling fees, as well as potential delays encountered by those currently using shipment brokers to manage direct international purchases.

The transition accompanies another milestone for InSphero Inc., which has assembled an expert team of 11 US-based employees over the past year. Says Hunt, “We’ve moved quickly, adding key scientific staff to lead the laboratory build-out, technology transfer, and initiate product manufacturing in our state-of-the-art Brunswick facility. Concurrently we have established an experienced team of sales managers, field application scientists, marketing, and product management professionals to provide responsive education and support to our North American customers.”

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Stewart Hunt
General Manager, InSphero Inc
Phone +1 800-779-7558 ext. 101
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting

InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting

Schlieren, Switzerland, January 25, 2016 – Study describes high-throughput compatible screening assay using 3D tumor microtissue models to classify efficacy, toxicity, and mechanism of action for compounds in NIH Oncology Library. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, will present preliminary findings from studies in collaboration with the NIH National Center for Advancing Translational Sciences (NCATS) and NMI Technologietransfer GmbH, at today’s annual meeting of the Society for Laboratory Automation and Screening (SLAS) in San Diego, California. Data summarizing screens of 40 compounds from the NCATS Oncology Library in 3D ovarian and pancreatic tumor microtissues will be presented by InSphero CSO and co-founder Dr. Jens M. Kelm during Monday afternoon’s Assay Development & Screening poster session.

InSphero and NCATS announced a collaboration in 2014 to develop improved phenotypic high-throughput screening (HTS) methodologies incorporating highly biologically relevant 3D tumor microtissue models that more closely mimic the in vivo tumor microenvironment than traditional 2-dimensional monolayer cell culture. 3D tumor microtissue co-cultures from ovarian or pancreatic tumor cell lines with stromal fibroblasts were generated using InSphero’s patented hanging drop technology. Stromal fibroblasts were engineered to express a secreted reporter to simultaneously assess both anti-tumor efficacy and non-specific cytotoxicity. Initial findings from the collaboration confirmed more than 50% of the 40 compounds tested displayed greater potency against ovarian and pancreatic tumor cells grown as 3D microtissues than to the same cells grown in monolayer. Furthermore, the screen identified three compounds that showed anti-tumor efficacy in ovarian tumor microtissues only in the tumor/fibroblast co-culture model, highlighting the potential importance of mimicking heterogeneous tumor microenvironments when conducting such high-throughput in vitro screens. Dr. Kelm notes that incorporating advanced multi-cell type 3D models derived from these and other types of cancer is critical to improving the translational value of in vitro screens.

“Here we’ve established a multi-parametric phenotypic screening method that not only factors in tumor size and cell viability, but also discriminates between anti-tumor and non-specific toxic effects of compounds. Using these results, we can determine a therapeutic index value by which compounds are ranked for their potential efficacy and specificity toward a particular cancer, using models that more accurately reflect in vivo tumor biology.” In addition to Dr. Kelm’s poster presentation, InSphero microtissues and high-throughput screening and imaging concepts will be featured during several events at SLAS2016, including two exhibitor tutorials and other collaborative posters.

For more information about NCATS, visit www.ncats.nih.gov.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Dr. Jens M. Kelm
Chief Scientific Officer and Co-founder
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

InSphero Adds Head of Sales, Expands Global Sales Team

InSphero Adds Head of Sales, Expands Global Sales Team

Schlieren, Switzerland, January 21, 2016 – Beate Schnell, Ph.D. joins senior team at global leader in 3D cell culture, announces new hires to support US and European growth. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, has appointed Dr. Beate Schnell to serve as Head of Sales. Dr. Schnell joins the InSphero senior management team having previously held senior-level strategic sales, sales operations, and key account management positions at Promega Corp., Promega GmbH, and Abbott Diagnostics. 

InSphero CEO and co-founder Dr. Jan Lichtenberg states the addition of Schnell “adds instant energy and over 15 years’ experience in the global life sciences research and diagnostics industry to lead our growing global sales team.  Beate brings with her a proven track record of setting and achieving ambitious sales objectives with one of our industry’s leading companies, and her scientific background and customer-centric sales focus make her a natural fit for InSphero.  We are excited to have her leading our team and driving our coordinated sales and marketing initiatives.” 

Along with the hiring of Schnell, InSphero’s sales team and facilities are expanding to meet increased demand within the US marketplace where InSphero’s  assay-ready 3D InSight™ Microtissues and contract screening services are gaining traction for safety and efficacy testing within the pharmaceutical industry.  States Lichtenberg, “In addition to Beate, we’ve recently added experienced regional account professionals and field application scientists in the US and Europe.  With the establishment of our US bioproduction facility in Brunswick, Maine, we have created capacity to provide responsive, best-in-class product delivery and support to our North American customers.”   

BSc

 

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

InSphero goes Greener

Product manuals to be delivered as digital documents

InSpheroFlashDrive

As part of our ongoing corporate initiative to be an environmentally responsible, "green" company, InSphero will begin delivering product manuals and other relevant technical documents in electronic format. Beginning in January 2016, product shipments will include an e-document-packed USB flash drive containing relevant product manuals and technical protocols. The most current version of technical documents, as well as product literature and application notes, will continue to be available for download on the support section of the InSphero website.

We need your help!
Your feedback and suggestions are important to us! Please help us continue to improve the quality of our products and customer support. Submit your feedback to This email address is being protected from spambots. You need JavaScript enabled to view it. or complete our plate feedback survey: https://www.surveymonkey.com/r/platefeedback

Tissue Engineering Publication Features InSphero Cardiac Microtissues

Tissue Engineering Publication Features InSphero Cardiac Microtissues

 

A recent paper from our collaborators at Bern University Hospital and Cellular Dynamics International (CDI), published in Tissue Engineering Part C: Methods, compares cardiomyocytes derived from iPSCs grown in traditional 2D cell culture to 3D cardiac microtissues formed using InSphero hanging drop technology. Their results show that 3D cardiac microtissues are free of necrosis and recapitulate vital cardiac functions, making them an ideal model system for testing new therapeutic strategies and detecting cardiotoxicity. 



Learn more about novel applications of 3D cardiac microtissues in development at InSphero:

View a complete list of InSphero Publications

InSphero Granted Hanging Drop Patent in United States

InSphero COO Melanie Aregger Receives 2015 Women's Business Award

InSphero COO and Head of InSphero Diagnostics Melanie Aregger recieves 2015 Women's Business Award "Megatrend Health"

Congratulations to InSphero COO and Head of InSphero Diagnostics Melanie Aregger, who on Tuesday, November 10 was honored with the 2015 "Megatrend Health" Women's Business award at the Women's Business Conference of the University of Lucern. Melanie Aregger was one of ten honorees at the 10th annual event, whith the guiding theme "visibility" of women in the economy and leading positions.

2015 07 16 13 22 58 AVScrollView 2

 

Interview with Melanie Aregger (German)

The keynote was opened by Swiss Federal Council Doris Leuthard, followed by discussions about institutional and media visibility, as well as personal visibility and self-branding.
Highlight of the event was the presentation of the ten winners of the Women's Business Award 2015. "Interesting women, which have, in representation of many others, achieved something extraordinary, something different and new. We want to give visibility to those achievements and person behind it" as project leader Sita Mazumder of the University of Lucern says.

University of Lucern press release (German)

More about the Women's Business Conference

Want to hear more InSphero success stories? Sign up for our newsletter or follow us on Twitter and LinkedIn

 

 

 

InSphero Granted Hanging Drop Patent in United States

InSphero Promotes Melanie Aregger to Chief Operating Officer

InSphero Promotes Melanie Aregger to Chief Operating Officer

Schlieren, Switzerland, November 24, 2015 – Head of InSphero Diagnostics division and senior team member promoted to assume role as COO. PDF Version

InSphero AG the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer.

Having joined InSphero in November 2013 as Business Development Manager, Ms. Aregger served on the management team and was promoted to Head of InSphero Diagnostics in 2014.  There she has built up the InSphero Diagnostics business unit, while assisting in the securing of Series C financing for InSphero AG, a round which netted CHF 20MM in July 2015. Her efforts in these responsibilities recently earned Melanie the 2015 Women’s Business Award by “Megatrend Health.”  In her new role as COO she will continue to drive the Diagnostics business as part of her business development responsibilities and also manage InSphero’s operations, purchasing and bioproduction functions. 

InSphero CEO and co-founder Dr. Jan Lichtenberg states, “With her entrepreneurial business acumen and profound professional experience including business-model analysis, change and risk management, supply-chain optimization and product launches, Melanie Aregger has been a key member of the InSphero management team for the past two years. Her leadership as COO will continue to benefit our global growth initiatives in both the drug-testing and diagnostics markets.”

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

A Network Sets Things in Motion: TEDD Celebrates its 5th Anniversary

At the Annual Meeting at ZHAW Waedenswil on 22 October 2015, the TEDD-Network (Tissue Engineering for Drug Development and Substance Testing) celebrated its 5th anniversary. Since its foundation, TEDD has become an internationally renowned competence centre and includes currently 91 members from academia and industry. They cover the entire development and value chain. 

“Coming together is a beginning, keeping together is progress; working together is success”. This comment of the American industrialist Henry Ford inspired Professor Ursula Graf- Hausner, Head of Research of Cell Culture Technology and Tissue Engineering at ZHAW Waedenswil, when in 2010 she founded the TEDD network together with InSphero AG, Swiss leading supplier of organotypic in vitro 3D micro tissues for drug testing. Convinced of the TEDD concept, Gebert Ruef Foundation funded the first steps.

Read full article

more about TEDD

TEDD Quote Jens

 

 

 

InSphero Granted Hanging Drop Patent in United States

InSphero CEO Jan Lichtenberg Receives EY Entrepreneur of the Year "Emerging Entrepreneur" Award

InSphero CEO and co-founder Jan Lichtenberg receives Swiss "Emerging Entrepreneur" award from EY. 

Congratulations to InSphero CEO and co-founder Dr. Jan Lichtenberg, who on Friday, October 23 was honored as the 2015 Swiss "Emerging Entrepreneur" at the EY Entrepreneur of the Year™ 2015 award ceremony held in Zurich, Switzerland.  Dr. Lichtenberg was one of four honorees at the 18th annual event, which also recognized the top Swiss entrepreneurs in Trade/Services, Industry/High-Tech/Life Sciences and Family Business categories. 

Ernst & Young press release:

Dr. Jan Lichtenberg: Building bridges with an eye for revolutions

The "Emerging Entrepreneur" category always features surprising entrepreneurs who dare to reconsider conventional practices and look at new ideas as the rule rather than the exception. In all economic sectors, this continually leads to useful innovations that make progress for the entire industry, and not just for the emerging entrepreneurs' companies. A great example is Dr. Jan Lichtenberg, who has won the award for Entrepreneur Of The Year 2015 in this category. With his biotech company InSphero AG, he aspires to bring about a revolution in testing practices in drug development, using his systems and materials to bring greater efficiency, reliability and effectiveness to the testing process. Organotypic 3-D micro-tissues are the centerpiece of the InSphero revolution. The jury was fascinated by the opportunities offered by Dr. Lichtenberg's innovation, and was impressed by his ability to concentrate the focus of a diverse, international research team of top specialists to target a common goal and stay on course. What's more, he also communicates eye-to-eye with investors. Dr. Lichtenberg is an entrepreneur of international standing and global potential, so it is no surprise that he can count himself among the winners of the Entrepreneur Of The Year award in 2015.

InSphero press release

JLi EY2015

Watch EY portrait video

Connect: https://twitter.com/EY_EOY

Want to hear more InSphero success stories? Sign up for our newsletter or follow us on Twitter and LinkedIn

 

 

 

InSphero Granted Hanging Drop Patent in United States

InSphero Receives € 750K Funding from EU-ToxRisk Consortium

InSphero Receives € 750K Funding from EU-ToxRisk Consortium

 

Schlieren, Switzerland, Oct 21, 2015 –In a large (€ 30 MM) H2020-supported collaborative project, leading cell culture technology provider joins consortium to jointly foster more efficient, animal-free chemical safety assessment.  PDF Version

InSphero AG, the leading provider of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has been awarded € 750K in funding over six years as part of the € 30 MM EU-ToxRisk collaborative project funded by Horizon 2020.

An international consortium of 39 partner organisations will be funded by the European Commission to work on the integration of new concepts for regulatory chemical safety assessment. These new concepts involve cutting-edge human-relevant in vitro non-animal methods and in silico computational technologies to translate molecular mechanistic understanding of toxicity into safety testing strategies. The ultimate goal is to deliver reliable, animal-free hazard and risk assessment of chemicals

Coordinated by Bob van de Water, Professor of Toxicology at the University Leiden (The Netherlands), EU-ToxRisk has the ambition to become the flagship in Europe for animal-free chemical safety assessment. The project will integrate advancements in cell biology, omics technologies, systems biology and computational modelling to define the complex chains of events that link chemical exposure to toxic outcome. The consortium will provide proof of concept for a new mechanism-based chemical safety testing strategy with a focus on repeated-dose systemic toxicity as well as developmental and reproductive toxicity. Importantly, novel mechanism-based test methods will be integrated in fit-for-purpose testing batteries that are in line with the regulatory framework and will meet industrial implementation. EU-ToxRisk will develop new ab initio quantitative risk assessment approaches based on understanding of so-called “Adverse Outcome Pathways” incorporating all mechanistic toxicity data available in the public domain. It will also achieve a rapid improvement of so-called “read across” approaches as the most important data-gap filling and hence animal-saving alternative method at present. Thus, the project strives towards faster safety evaluation of the many chemicals used by industry and the society.

InSphero CSO and co-founder Dr. Jens Kelm says the award, “serves as a key indicator of the value being placed on advanced 3D models in the project, as they provide greater longevity to enable repeat-dose testing in vitro, and improved biological relevance and mechanistic accuracy relative to traditional 2D cell culture models.   Much of the in silico and predictive modelling algorithms are based upon large amounts of data accumulated using 2D models, so 3D microtissues stand to be a valuable resource in helping to update and refine that data to increase its predictive value.  We are excited to lend our expertise in developing and producing a diverse range of organotypic microtissues, implementing state-of-the-art 3D optimized assays, and integrating microtissues into Body-on-a-Chip systems to advance the aims of the consortium.” 

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

Oliver Krähenbühl Named as InSphero CFO

Addition of internationally experienced finance manager strengthens senior team.

InSphero announced today that Oliver Krähenbühl has been hired to serve as Chief Financial Officer. Mr. Krähenbühl joins the InSphero senior management team having previously held CFO positions at HF Global Inc. New York, Canon, and JobCloud AG, the leading Swiss online professional recruiting company.  Read the press release

Portrait Juli 2015

 

InSphero Granted Hanging Drop Patent in United States

Publication: Bone Microtissues Made in GravityPLUS Improve Implants

Best of Both Worlds: GravityPLUS™ publication advances scaffold-based bone implant technology using scaffold-free microtissues

A new generation of biomaterials focus on smart materials incorporating cells.  In this recent InSphero publication in the journal Materials, the authors describe a novel generation of synthetic nanofibrous implant functionalized with scaffold-free living 3D microtissues grown in the InSphero GravityPLUS™ Hanging Drop System.  The regenerative medicine strategy enhances the effectiveness of therapeutic implants compared to current strategies based on adding single cells to the implanted scaffold. 

 

Bone microtissue 
Bone microtissue grown in InSphero's GravityPLUS™ Hanging Drop System

InSphero 006 20150826

The InSphero GravityPLUS™ Hanging Drop System is InSphero's patented scaffold-free 3D cell culture platform.  It includes the GravityPLUS™ Hanging Drop Plate for microtissue production, and the companion GravityTRAP™ plate for microtissue culture and assay. 

 

More information about InSphero's products and services 

InSphero Granted Hanging Drop Patent in United States

Publication: Adding the 'heart' to hanging drop networks for microphysiological multi-tissue experiments.

Beating cardiac microtissues added to hanging drop BoC networks.

Reasearchers at the ETH Zurich have added beating cardiac microtissues developed by InSphero into a novel microfluidic device that can synchronize the beating microtissue with unidirectional pulsed- or continuous flow of culture medium throughout an interconnected hanging drop microtissue network. Read the full article describing this next-generation Body-on-a-Chip concept published in the Sept 15 issue of the journal Lab on a Chip (open access until November 19, 2015), and read the feature article on the publication in Chemistry World.

Synchronously beating neonatal rat cardiomyocytes in 3D:

 

Learn more about cardiac microtissues:

Poster: Transmembrane Potential Measurements in Cardiac Microtissues Derived from Human Stem Cells

Webinar: Introduction to Cardiac Microtissues and Assaying Electrical Activity, Intracellular Calcium and Contractility in Cardiac Microtissues Using CellOPTIQ Platform from Clyde Biosciences 

 

More information about InSphero's products and services 

 

InSphero Granted Hanging Drop Patent in United States

InSphero Launches 14 Day Hepatotoxicity Testing Service

Service offers convenient monthly runs at $990 per compound to streamline DILI testing in 3D primary human hepatocytes

As part of our growing portfolio of in-house standardized 3D InSight™ testing services, InSphero has launched a 14 Day Hepatotoxicity Testing Service to simplify DILI testing in patent-pending 3D InSight™ Human Liver Microtissues.  At just $990 per compound, customers receive repeat-dose 14 day toxicity assessment in primary human hepatocyte/Kupffer cell co-culture microtissues, with results returned three weeks after the initial dosing.  IC50 dose-response curves are delivered for the test compound(s) as well as vehicle control and two positive controls (Chlorpromazine and Ketoconazole) using the Promega CellTiter-Glo® Cell Viability Assay (measuring total spheroid ATP content).  Monthly runs initiate on the first Tuesday of every month beginning November 3 and December 1, 2015.   

How will your compounds perform in 3D? 

Click here for details, or contact This email address is being protected from spambots. You need JavaScript enabled to view it. to request a quote or place an order. 

14 day your compound here

InSphero Granted Hanging Drop Patent in United States

InSphero Granted Hanging Drop Patent in United States

InSphero Granted Hanging Drop Patent in United States

Schlieren, Switzerland, September 29, 2015 – Patent establishes protection of InSphero GravityPLUS™ technology in all major global markets, key milestone for leading provider of 3D cell culture platforms, microtissues and services.  PDF Version

The United States Patent and Trademark Office (USPTO) officially granted InSphero AG full protection of its GravityPLUS™ hanging drop technology.  InSphero, the world's leading developer of easy-to use solutions for organotypic 3D cell culture models and body-on-a-chip systems, now holds hanging drop patents in the world's major pharmaceutical and biotechnology markets, including the United States, Europe, China, Japan, and Singapore. The core patent WO2010031194 describes multi-well plates which allow the generation of hanging drops for 3D cel culture, using convenient top loading of the cell suspension.

InSphero commercialized the hanging drop technology as the GravityPLUS™ Hanging Drop System in 2010.  The system includes the GravityPLUS™ plate used for production of 3D spheroids in hanging drops, and also the companion GravityTRAP™ culture and assay plate, to which 3D microtissues are transferred for long-term culture and drug testing. 

Dr. Jan Lichtenberg, CEO and co-founder of InSphero, says that the favorable decision has been a long time coming for InSphero.  “We are excited the USPTO has recognized the originality of our design, and granted protection of the investment we have made into the creation of new technology.  This protection allows us to operate unhindered in the US market, gives our customers there added confidence to invest in InSphero technology as their platform of choice for 3D cell culture, and provides the grounds necessary to defend against industry competitors attempting to imitate our technology.”

Granting of the patent on September 8 followed InSphero’s recent completion of a Series C financing round , and August announcement naming PerkinElmer as the exclusive global distributor of InSphero hanging drop and ultra-low attachment (ULA) plates for 3D cell culture. 

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

AstraZeneca to present pancreatic microislet data at EASD Annual Meeting

AstraZeneca to present pancreatic microislet data at EASD Annual Meeting 

EASD2015

The 51st annual European Association for the Study of Diabetes (EASD) meeting will take place in Stockholm, Sweden September 14-18.  It is the largest international scientific meeting on diabetes and its complications.  One of the more than 1200 abstracts being presented this year will feature work performed by AstraZeneca's Dr. Eva-Marie Andersson and colleagues using InSphero 3D InSight™ Pancreatic Microislets.  You can view the abstract entitled "Human pancreatic microislets as a standardised model for glucose stimulated insulin and glucagon secretion" on the EASD virtual meeting website.

Learn more about our long-lived, standardized 3D islet model system for diabetes and metabolism research by visiting the product page, or viewing our on demand webinar: 3D InSight™ Human Pancreatic Microislets and the Combined Power of HTRF® Technology.

Human Islets

    

InSphero 3D Cell Culture Platforms Now Available Exclusively Through PerkinElmer

PE Announcement

The GravityPLUSTM Hanging Drop System and GravityTRAPTM ULA Plates are now EXCLUSIVELY available through PerkinElmer  

We are excited to inform you that InSphero and PerkinElmer have entered into a partnership making PerkinElmer the exclusive global distributor of our GravityPLUSTM and GravityTRAPTM 3D cell culture plates.  Read the Press Release

Our partnership with PerkinElmer will help make our industry-leading GravityPLUSTM Hanging Drop System and GravityTRAPTM ULA Plate technologies more readily available to a global customer base and simplify logistics associated with world-wide ordering and delivery.  We assure you that PerkinElmer will honor you as their customer in the same way we have, and that their products will bring added value to your 3D cell culture research.

Beginning July 21, 2015 we ask that you please place orders for InSphero plates through PerkinElmer. Please read the attached bulletin closely for a list of affected InSphero products and the new PerkinElmer part numbers, along with answers to Frequently Asked Questions about placing orders through PerkinElmer.

Other 3D InSightTM products from InSphero are not affected by this distribution agreement, therefore please continue to order assay-ready 3D microtissues, cell culture media, assay kits and services directly through InSphero.

In case of any remaining questions, kindly contact This email address is being protected from spambots. You need JavaScript enabled to view it.

InSphero Secures CHF 20 Million Series C Financing

InSphero AG Secures CHF 20 Million Series C Financing

fireworks 260x180

Celebratory fireworks may be the July theme in the United States and France, but InSphero's securing of CHF 20 million in Series C financing from WILD Group Management LLC, is triggering pyrotechnic-worthy celebration in Schlieren, Switzerland as well.  The recently finalized investment, announced in Wednesday's press release, is being used to rapidly expand InSphero's global footprint and broaden its portfolio of novel 3D microtissues and contract research services for 3D drug safety and efficacy testing. 

InSphero CEO Dr. Jan Lichtenberg says, "this investment is an affirmation of InSphero's valuable, more predictive liver, islet and tumor model systems for use throughout the drug development process," and is a direct result of the growing adoption of InSphero's 3D models by major pharma companies since 2014. 

Read the entire press release here, and thank you to all of our dedicated employees, loyal customers, strategic business partners, and key investors for helping us achieve the latest milestone in InSphero's rapidly evolving success story! 

Replay NOW: InSphero 3D Summer School Webinar Series 2015

2015 InSphero Summer School2

InSphero 3D Summer School Webinar Series 2015 - A great way to learn how 3D cell culture is simply more relevant!

InSphero's 2015 3D Summer School Webinar Series was back by popular demand! We had expanded this unique online event series to help you keep in touch with the latest in 3D cell culture technology and applications during summer time. A great opportunity to learn in an online format, making it easy to attend topics of greatest interest to you!

From basic 101 classes on 3D cell culture, to advanced sessions focused on cancer biology, toxicology and more, our 2015 webinar series gathered high-quality speakers and participants from industry and academia spanning a wide range of 3D knowledge and experience. 

Replay

Want to be among the first to know about upcoming webinars? Sign up for our newsletter

July 27 - August 7 - InSphero 3D Summer School Webinar Series 2015

2015 InSphero Summer School2

InSphero 3D Summer School Webinar Series 2015 - A great way to learn how 3D cell culture is simply more relevant!

InSphero's 2015 3D Summer School Webinar Series is back by popular demand! We've expanded this unique online event series to help you keep in touch with the latest in 3D cell culture technology and applications during summer time. This is a great opportunity to learn in an online format, making it easy to attend topics of greatest interest to you!

From basic 101 classes on 3D cell culture, to advanced sessions focused on cancer biology, toxicology and more, our 2015 webinar series gathers high-quality speakers and participants from industry and academia spanning a wide range of 3D knowledge and experience. Attend one or attend them all at no cost.

  • 1+ webinar per day over 2 weeks
  • Presentations from 3D cell culture and application experts from industry, academia, InSphero and our partners
  • Topics from general overviews to specific applications for safety, efficacy, and disease modeling

Date: Monday, July 27 to Friday, August 07, 2015

 

Registration now open!

Planned Webinar Topics Include:

  • An introduction to 3D cell culture techniques and the benefits of scaffold-free systems
  • 3D optimized endpoints and cell based assays for spheroid analysis
  • Metabolic profiling of 3D microtissues
  • 3D tumor models for drug discovery
  • High throughput size profiling of tumor spheroids  
  • 3D liver microtissue models for toxicity testing
  • High content imaging of liver microtissues  
  • 3D pancreatic, cardiac, and neuronal model systems for toxicity testing and disease modeling
  • The Body on a Chip - modeling complex multi-organ systems using microtissues and microfluidics  


Earn your InSphero Ph.3D. and get the chance to win a $500 travel grant!
 

1230028 Green Mortar Board Graduation Cap Icon

  • Attend any 4 InSphero 3D Summer School sessions, and you'll earn a unique InSphero Ph.3D. diploma!
  • Attend 5 or more InSphero 3D Summer School sessions and qualify for the Grand Prize drawing of a $500 travel grant to a 2015 or 2016 meeting hosted by one of the following:
    AACR
    EORTC
    SOT
    ESTIV
    InSphero User Group Meeting

  • Can't attend that many sessions? No worries, you'll still have a chance to win! For each 3D Summer School session you attend, your name will be entered into a drawing to win 1 of 5 revolutionary SWATCH SISTEM51 series watches in the color of your choice. The more you attend, the more you learn...and the better your chance of winning!
  • Want to be among the first to know about upcoming webinars? Sign up for our newsletter

SOLD OUT - InSphero UK User Group Meeting

 UGM UK Banner

 

Register NOW! 

2015 InSphero UK
User Group Meeting

 


Limited seating available.

Date: 11 June, 2015

Venue: The Trinity Centre, Cambridge

sout

Please put me on the waiting list!*

* the waiting list will be considered if a registered participant will cancel his participation prior to the User Group Meeting. Slots will be filled according to the date of the e-mail sent to us with a request to be placed on the waitinglist. For questions, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.


Current Agenda

 


10:00 - 10:30       Welcome Reception and Introduction
                                by Tony Rutt of InSphero


10:30 – 11:00      3D InSightTM Services Overview
                               by Dr. Johannes Haugstetter of InSphero


11:00 – 11:30     Compound Classification Strategies Using Homo- 
                               and Heterotypic Tumor Microtissues
                               by Zoe Weydert, Master of Science at Zurich 
                               University of Applied Sciences (ZHAW)


11:30 – 12:00     Applications of in vitro assays to measure cellular 
                               response in 3D cell cultures 
                               by Dr. Marta Rucka of Promega

12:00 – 13:00      Networking Lunch incl. Live Demonstration

13:00 – 13:30      Understanding Cellular Metabolism of Spheroids 
                               Using Extracellular Flux Technology 
                               by Dr. Alex Liversage of Seahorse Bioscience
 

13:30 – 14:00      Use of Liver Microtissues for Drug Safety 
                               Assessment: an AstraZeneca Perspective 
                               by Alison Foster of Astra Zeneca

14:00 - 14:15       Short Break
  
14:15 – 14:45      Optical measurements of electrical activity and 
                               contraction from cardiac microtissues of 
                               iPS-derived cardiomyocytes
                               by Dr. Maria Hortigon, University of Glasgow 
                               and Clyde Biosciences Ltd., UK


14:45 – 15:15      Proteomic Profiling of 3D Human Liver
                               Microtissues
                               by Dr. Claudia Escher of Biognosys


15:15 – 16:00      Wrap up & Networking Coffee
                               by Tony Rutt of InSphero

 

 

Want to be among the first to know about future UserGroup Meetings? Sign up for our newsletter

 

 

GEN Tutorial Quantifies BSEP and MRP2 Activity in 3D Liver

Our latest tutorial "Quantifying Efflux Activity in 3D Liver Spheroids" in Genetic Engineering and Biotechnology News (GEN) highlights the use of 3D InSightTM Human Liver Microtissues to assess bile salt export pump (BSEP) and multidrug resistance-associated protein 2 (MRP2) activity using fluorescent probes quantified with the PerkinElmer Opera PhenixTM High Content Screening System. 

Read the tutorial or learn more about 3D InSightTM liver microtissues

 GEN tutorial

CFDA staining of bile canaliculi in 3D InSightTM Human Liver Microtissues visualized in the PerkinElmer Opera PhenixTM

News Archive

 

Company video

company-video-inspheor